LEXX Company Profile and Key Details

Q: Who are the executives of LEXX?

Dr. Philip N. Ainslie Ph.D.Advisor & ConsultantMr. Christopher A. BunkaChairman & Chief Executive OfficerMr. John M. Docherty M.Sc.Pres & DirectorVanessa CarleHead of LegalMr. Gregory John Downey CMA, CPAChief Financial Officer & TreasurerKristin HamiltonDirector of OperationsMr. Mike ShankmanChief Financial Officer

NASDAQ : LEXX

Lexaria Bioscience

$0.65

0.0432+7.13%

Open: 3:24 PM

64.98

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Lexaria Bioscience Corp. (LEXX) stock surged +7.13%, trading at $0.65 on NASDAQ, up from the previous close of $0.61. The stock opened at $0.63, fluctuating between $0.61 and $0.68 in the recent session.

Stock Snapshot

0.6056

Prev. Close

13.26M

Market Cap

0.6117

Day Low

-1.38

P/E Ratio

-0.47

EPS (TTM)

-663266.25

Cash Flow per Share

0.63

Open

20.44M

Number of Shares

0.68

Day High

87.16%

Free Float in %

413464.75

Book Value

15.44K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 21, 2026	0.57	0.62	0.57	0.61	106.81K
May 20, 2026	0.59	0.61	0.58	0.58	142.54K
May 19, 2026	0.57	0.59	0.55	0.58	69.16K
May 18, 2026	0.59	0.60	0.56	0.56	54.06K
May 15, 2026	0.62	0.62	0.58	0.59	43.42K
May 14, 2026	0.62	0.65	0.61	0.61	120.78K
May 13, 2026	0.57	0.64	0.55	0.60	193.14K
May 12, 2026	0.62	0.63	0.58	0.58	305.14K
May 11, 2026	0.61	0.65	0.60	0.60	93.49K
May 08, 2026	0.64	0.65	0.60	0.61	267.26K
May 07, 2026	0.67	0.69	0.62	0.64	250.78K
May 06, 2026	0.70	0.72	0.66	0.67	155.04K
May 05, 2026	0.67	0.73	0.67	0.69	82.06K
May 04, 2026	0.71	0.72	0.67	0.67	61.78K
Apr 30, 2026	0.70	0.72	0.55	0.66	321.98K
Apr 29, 2026	0.91	0.91	0.68	0.69	776.49K
Apr 28, 2026	0.98	0.98	0.87	0.88	124.5K
Apr 27, 2026	0.97	1.01	0.94	0.95	104.87K
Apr 23, 2026	0.96	0.97	0.91	0.94	157.51K
Apr 22, 2026	0.94	0.99	0.93	0.97	116.38K

Contact Details

Kelowna, BC V1X 2P7

Canada

https://www.lexariabioscience.com 250 765 6424

About Company

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Stock Peers

ARGX

11.97+1.49%

argenx SE$816.22 REGN

-7.17-1.10%

Regeneron Pharmaceuticals, Inc.$642.59 UTHR

1.94+0.34%

United Therapeutics Corporation$565.87 MDGL

0.12+0.02%

Madrigal Pharmaceuticals, Inc.$513.59 VRTX

3.1+0.72%

Vertex Pharmaceuticals Incorporated$433.54 PRAX

14.95+4.45%

Praxis Precision Medicines, Inc.$350.56 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.18+0.72%

Krystal Biotech, Inc.$304.23 ALNY

2.03+0.68%

Alnylam Pharmaceuticals, Inc.$300.51 ASND

6.17+2.56%

Ascendis Pharma A/S$247.51

Company Overview

Lexaria Bioscience Corp. (NASDAQ:LEXX) closed at $0.65 USD, gaining $0.04 (7.13%) from the previous close of $0.61. The stock is currently mid-range between its 52-week high and low $0.46 and $1.55. With a market capitalization of about $13.26 million, Lexaria Bioscience Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.36). Key stats such as the average daily volume over the past year has been around 179.58 thousand shares, volume is running light vs its 52-week average. Headquartered in Kelowna, BC, Lexaria Bioscience Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard C. Christopher, the company employs approximately 7 people and listed since January 12, 2021. Lexaria Bioscience Corp. operates as a biotechnology company.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 4.44%, SMA50 2.18%, SMA200 -21.69%). The stock’s 14-day RSI is 52.52 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -62.09% below its high and over 56.2% above its low. Average 10-day trading volume of 129.38 thousand shares is below the 3-month average of 184.31 thousand, indicating normal recent market interest.

Valuation Metrics

Lexaria Bioscience Corp. trades at a P/E ratio of -1.58, slightly below the S&P 500 average, with a price-to-sales ratio of 34.24 and a price-to-book ratio of 2.28 suggesting the stock is closer to book value. The P/FCF stands at -1.34, also above market averages.

Dividend & Fair Value

Lexaria Bioscience Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.69. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Lexaria Bioscience Corp. generated EPS of -$0.57 over the past year. Five-year average earnings growth is 14.15%. Wall Street analysts project EPS growth of 24.86% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.10. Next year's EPS is expected at $16.67. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $4.00. The high target offers 719.67% upside. The low target suggests 555.74% downside. The mean target is $4.33. This offers 609.84% upside. Lexaria Bioscience Corp. earnings surprise history is frequent misses against expectations. The quarter that ended April 13, 2026, missed forecasts by -40.0%. The prior quarter beat by -46.15%. Over the last six quarters, Apple has recorded several small beats. These include 40.0% in July 14, 2025.

Shareholding & Insider Activity

Lexaria Bioscience Corp. has 19.56 million shares outstanding. The public float is 16.95 million shares, elevated short interest at 1.78% of float. This equals 313.06 thousand shares. The short ratio is 1.82 days. Institutional investors hold 12.65% of the float. Insiders own 7.13%. BUNKA CHRISTOPHER holds 281.91 thousand shares, Baxter Nicholas W has 160.00 thousand shares and CHRISTOPHER RICHARD has 65.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Lexaria Bioscience generated $705.92K in revenue, or $0.04 per share. Gross margin was 99.61%, operating margin -1683.01%, and net profit margin -1686.00%. Returns are negative, with ROA at -285.07% and ROE at -398.10%.
On valuation metrics, Lexaria Bioscience trades at a P/E of -1.58, P/S of 34.24 and P/B of 2.28. The current ratio is 26.88 and quick ratio is 26.88. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -109.15 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -99.32.

Quarterly Financial Highlights

For the quarter ended Aug 31, 2025, Lexaria Bioscience posted revenue of $705.92K, down slightly from $464.28K in the prior quarter. Gross profit was $587.35K (margin 83.20%). Operating income was - $11.63M (margin -1648.0%). Net income was- $11.90M (EPS - $0.66).
The company ended the quarter with $1.95M in cash and short-term investments, a total debt of $109.32K, and net debt of - $1.69M. Total assets were $4.18M, with equity of $2.60M. Financials further reflected weakness, with operating cash flow of - $10.45M, free cash flow of - $10.45M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Lexaria Bioscience Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.69%, with price expected at $0.45 by June 03, 2026, within a range of $0.32 to $0.59 3-Month Outlook: Projected fall of -65.32%, reaching $0.21 by August 19, 2026, with a range of $0.16 to $0.26. 1-Year Outlook: Projected gain of 215.39%, with price at $1.91 by May 21, 2027, within a range of $0.00 to $1.00.

Key Takeaways

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are up 19.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lexaria Bioscience Corp. trading at a premium to the broader market with a P/E of -1.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.89, suggesting 1037.71% upside. Our AI forecast model points to short-term weakness (-25.69% over two weeks), a medium-term fall (-65.32% over three months), and a longer-term gain (215.39% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Lexaria Bioscience Corp. (LEXX) stock price?

Lexaria Bioscience Corp. (NASDAQ: LEXX) stock price is $0.65 in the last trading session. During the trading session, LEXX stock reached the peak price of $0.68 while $0.61 was the lowest point it dropped to. The percentage change in LEXX stock occurred in the recent session was 7.13% while the dollar amount for the price change in LEXX stock was $0.04.

LEXX's industry and sector of operation?

The NASDAQ listed LEXX is part of Biotechnology industry that operates in the broader Healthcare sector. Lexaria Bioscience Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LEXX?

Dr. Philip N. Ainslie Ph.D.
Advisor & Consultant
Mr. Christopher A. Bunka
Chairman & Chief Executive Officer
Mr. John M. Docherty M.Sc.
Pres & Director
Vanessa Carle
Head of Legal
Mr. Gregory John Downey CMA, CPA
Chief Financial Officer & Treasurer
Kristin Hamilton
Director of Operations
Mr. Mike Shankman
Chief Financial Officer

How LEXX did perform over past 52-week?

LEXX's closing price is 31.65% higher than its 52-week low of $0.46 where as its distance from 52-week high of $1.55 is -60.93%.

How many employees does LEXX have?

Number of LEXX employees currently stands at 7.

Link for LEXX official website?

Official Website of LEXX is: https://www.lexariabioscience.com

How do I contact LEXX?

LEXX could be contacted at phone 250 765 6424 and can also be accessed through its website. LEXX operates from 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7, Canada.

How many shares of LEXX are traded daily?

LEXX stock volume for the day was 15.44K shares. The average number of LEXX shares traded daily for last 3 months was 179.58K.

What is the market cap of LEXX currently?

The market value of LEXX currently stands at $13.26M with its latest stock price at $0.65 and 20.44M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	7
Beta	0.48
Sales or Revenue	$705.92K
5Y Sales Change%	-0.654%
Fiscal Year Ends	August
Sector	Healthcare
Industry	Biotechnology

LEXX Company Profile and Key Details

Lexaria Bioscience

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics